Due to the inefficacy of the current treatment regimen, patients with glioblastoma multiforme (GBM), only have a median survival rate of 10–15 months. Temozolomide is the FDA-approved chemotherapeutic agent for the treatment of this lethal disease. A plant-derived compound, such as vanillin (4-hydroxy-3-methoxybenzaldehyde), could be a promising agent for GBM treatment due to its anti-oxidant, neuroprotective, and anti-bacterial activities, and its ability to cross the blood-brain barrier. Vanillin is commonly used as a flavouring agent in beverages and food. The purpose of this study is to explore the effect of vanillin on the human GBM LN229 cell line. The impact of vanillin treatment on cell migration and single-cell colony formation was examined using a wound-healing and soft agar assay, respectively. According to our findings, vanillin inhibited the proliferation of GBM cells. The treatment with vanillin reduced the number of migratory cells and inhibited the capacity of a cell for colony formation in the LN229 cell line. In conclusion, vanillin could be effective in preventing the growth of tumours and might be a potential phytotherapeutic agent for GBM treatment.
Key words: Brain tumor; MTT; Phytocompound; Soft agar; Wound healing
|
